2014 – Virobay completes $8 million Series B preferred stock financing more
2014 – Virobay announces the appointment of James Welch as Chief Financial Officer more
2014 – Virobay appoints Thomas J. Dietz, Ph.D. to the Virobay Board of Directors more
2013 – Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain more
2013 – Virobay and LEO Pharma initiate a Phase 1 Trial of VBY-891, a compound intended for oral treatment of psoriasis more
At Virobay we are developing protease inhibitors for the treatment of autoimmune diseases, neuropathic pain, liver diseases and cancer.
Our virtual model of drug discovery and development combines extensive in-house expertise with the resources of contract research and manufacturing facilities worldwide for cost effective and efficient development.